TWST Twist Bioscience Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1581280 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.0%
TTM net income YoY-67.6%
TTM EPS YoY-60.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—
Margins
Gross margin52.4%
Operating margin-30.4%
Net margin-28.3%
FCF margin-19.4%
EBITDA margin-24.7%
Returns
ROE-19.1%
ROA-14.8%
ROIC (approx.)-34.2%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets20.8%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue10.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-09-30 | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $459.43M | $376.57M | $312.97M | $245.11M | $203.56M |
| Cost of revenue | $218.63M | $185.57M | $179.62M | $155.38M | $119.33M |
| Gross profit | $240.80M | $191.00M | $133.35M | $89.73M | $84.23M |
| R&D expense | $71.84M | $80.28M | $90.85M | $106.89M | $120.31M |
| SG&A expense | $301.21M | $246.98M | $218.40M | $189.74M | $212.95M |
| Operating income | -$139.46M | -$136.26M | -$220.83M | -$217.16M | -$234.78M |
| Interest expense | — | — | $29,000 | $5,000 | $80,000 |
| Pretax income | -$129.80M | -$76.95M | -$208.17M | -$203.47M | -$228.27M |
| Income tax | $406,000 | $719,000 | $560,000 | $1.15M | -$10.41M |
| Net income | -$130.20M | -$77.67M | -$208.73M | -$204.62M | -$217.86M |
| EBITDA | -$112.97M | -$111.41M | -$189.40M | -$187.85M | -$218.26M |
| EPS (basic) | -2.08 | -1.30 | -3.60 | -3.60 | -4.04 |
| EPS (diluted) | -2.08 | -1.30 | -3.60 | -3.60 | -4.04 |
| Weighted avg. shares (diluted) | 62.62M | 59.81M | 58.02M | 56.88M | 53.88M |
| Balance sheet | |||||
| Cash & equivalents | $533.99M | $183.05M | $229.13M | $289.28M | $380.26M |
| Short-term investments | $47.91M | $49.38M | $50.08M | $49.94M | $126.28M |
| Receivables | $70.19M | $57.02M | $34.90M | $44.06M | $40.29M |
| Inventory | $46.41M | $28.31M | $24.08M | $32.06M | $39.31M |
| Current assets | $737.22M | $332.97M | $346.78M | $424.26M | $596.48M |
| PP&E, net | $122.32M | $102.28M | $102.52M | $131.83M | $139.44M |
| Goodwill | $82.19M | $82.19M | $85.81M | $85.81M | $85.81M |
| Intangibles | $34.16M | $13.43M | $14.48M | $54.48M | $59.74M |
| Total assets | $1.12B | $641.86M | $614.32M | $776.40M | $961.38M |
| Current liabilities | $125.81M | $91.41M | $71.01M | $73.32M | $90.66M |
| Short-term debt | — | — | — | — | $0 |
| Total liabilities | $233.79M | $168.90M | $141.63M | $152.97M | $171.99M |
| Shareholders' equity | $888.02M | $472.96M | $472.69M | $623.43M | $789.38M |
| Shares outstanding | 67.81M | 60.63M | 58.88M | 57.56M | 56.52M |
| Cash flow statement | |||||
| Operating cash flow | -$41.43M | -$47.63M | -$64.09M | -$142.47M | -$124.39M |
| Capital expenditure | $47.58M | $28.00M | $5.08M | $27.78M | $101.86M |
| Free cash flow | -$89.01M | -$75.63M | -$69.17M | -$170.25M | -$226.24M |
| Investing cash flow | -$53.09M | -$24.76M | -$3.07M | $50.61M | -$232.93M |
| Financing cash flow | $446.68M | $28.54M | $6.89M | $911,000 | $270.53M |
| Depreciation & amortization | $26.48M | $24.85M | $31.43M | $29.31M | $16.51M |
| Stock-based compensation | $69.86M | $64.46M | $50.92M | $30.28M | $79.66M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.